The biotech giant also outlined an inverse Uber-style surge fee to reward people donating blood outside peak hours.
On Monday it outlined why it thinks its business is largely shielded.Biotechnology giant CSL argues an ageing population will help shield its business from any falloutweight loss, and potentially undermining its investment in therapies targeting kidney disease.
The plans were outlined at an investor day for CSL, a $116 billion company that is one of Australia’s big biotechnology growth stories, evolving from a government-owned enterprise established in 1916 to having 30,000 staff delivering products in more than 100 countries.with margins in blood collection centres under pressure and rivals planning to launch generic drugs against its iron deficiency product, Ferinject.
CSL head of research and development Bill Mezzanotte maintained the patients in the trial only represented a “small percentage of the overall dialysis patient population, which of course is only a small percentage of the business”. “However, offset by that, GLP-1s will do nothing for ageing,” he said. “And the overall population remains to continue to age, and that will likely balance the effect and keep the number of in total, relatively constant.”
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
CSL boss Paul McKenzie insists Ozempic won’t slim growthCSL boss Paul McKenzie finds himself in a position his predecessors haven’t faced for years: defending the blue chip’s growth prospects, including from the threat of new obesity drugs.
Read more »
Ozempic short-selling wave storms ASX; CSL, ResMed affectedAlarm bells are ringing on Wall Street about the toll of the diabetes drug, which is also used to treat weight loss and has flattened CSL’s valuation.
Read more »
CSL share price: What’s been eating CSL? One of Australia’s great listed businesses feels the Ozempic effectOne of Australia’s most loved businesses has come under attack from two powerful macro forces. It must now convince investors it’s the same old CSL.
Read more »
Our biggest healthcare company says it isn’t scared of OzempicCSL has outlined its growth strategy to investors and played down concerns about weight-loss drugs’ impact on some of its key products.
Read more »
Our biggest healthcare company says it isn’t scared of OzempicCSL has outlined its growth strategy to investors and played down concerns about weight-loss drugs’ impact on some of its key products.
Read more »
Is he the odd man out ... or ‘untouchable’? Big Giddey question for NBA’s sleeping giantNBA: Three-time NBA All-Star Ben Simmons recorded a solid performance for the Brooklyn Nets in a preseason game vs. the Los Angeles Lakers.
Read more »